Last reviewed · How we verify

NCT04803643

Upper Extremity Exercise Capacity, Muscle Oxygenation, Balance in Patients With Cystic Fibrosis

Completed Last updated 6 April 2023
What this trial tests

trial in Cystic Fibrosis in 60 participants. Completed in 15 March 2022.

Timeline
16 March 2021
Primary endpoint
28 February 2022
15 March 2022

Quick facts

Lead sponsorGazi University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date16 March 2021
Primary completion28 February 2022
Estimated completion15 March 2022
Sites2 locations across Turkey (Türkiye)

Conditions studied

Sponsor

Gazi University

Who can join

Adults 6 to 18, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of the study is to evaluate upper extremity exercise capacity, muscle oxygenation, balance and physical activity level in patients with cystic fibrosis.. The secondary aim of the study is assessment of functional exercise capacity, respiratory function, peripheral and respiratory muscle strength, respiratory muscle endurance, quality of life in patients with cystic fibrosis and compare them with healthy controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

Other Gazi University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04803643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing